西班牙IBD-PODCAST:近距离观察IBD管理中的当前日常临床实践
P Vega1, J M Huguet2, E Gómez3
1Complejo Hospitalario Universitario de Ourense, Orense, Spain.
Digestive diseases and sciences
|January 13, 2024
概括
许多炎症性肠病 (IBD) 患者的疾病控制能力不足,导致生活质量下降和医疗保健成本增加. 对于克罗恩病 (CD) 和性结肠炎 (UC) 患者,需要更好的治疗策略.
科学领域:
- 胃肠病学和肝病学 胃肠学和肝病学
- 临床研究 临床研究
- 炎症性肠病 (IBD) 研究 研究 研究 研究
背景情况:
- 炎症性肠道疾病 (IBD),包括克罗恩病 (CD) 和性结肠炎 (UC),可以导致无法逆转的肠道损伤和显著的长期并发症.
- IBD的低最佳控制与医疗保健资源利用率 (HCRU) 的增加,生活质量 (QoL) 的下降以及工作生产率的降低有关.
研究的目的:
- 评估IBD患者中患有低于最佳疾病控制的比例.
- 评估IBD控制在患者的QoL,HCRU和工作生产率上的影响.
主要方法:
- 在IBD-PODCAST研究中,采用了横截面的多中心设计.
- 基于使用STRIDE-II标准和患者/医生报告的措施的最佳或亚最佳控制的特征性CD和UC患者.
- 报告的结果来自西班牙队列,包括396名患者.
主要成果:
- 超过一半的CD患者 (53.1%) 和41.5%的UC患者表现出低于最佳的疾病控制.
- 尽管针对性免疫调节剂的使用率很高 (72.7%在CD中,40.9%在UC中),但低于最佳的控制仍然存在.
- 与最佳控制的患者相比,低最佳控制的IBD患者报告了 QoL 损失,HCRU 增加,直接成本增加和工作生产率下降.
结论:
- 显著的百分比的IBD患者,即使是那些有针对性的免疫调节剂的患者,也根据STRIDE II标准表现出低于最佳的疾病控制.
- 低于最佳的控制与QoL,工作生产力和HCRU的重大负面影响有关.
- 显然需要改进治疗方法,以加强IBD管理中的疾病控制.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
334
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
334
Drugs for Treatment of Ulcerative Colitis in IBD
142
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
142
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
Inflammatory Bowel Disease V: Surgical Management
147
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
147
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
120
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
120


